Lineage Cell Therapeutics, Inc. Non Peo Neo Avg Total Comp Amt
Lineage Cell Therapeutics, Inc. (LCTX) reported Non Peo Neo Avg Total Comp Amt of $992.08 thousand for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-29.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-29
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $992.08K DEF 14A · filed 2026-04-29 |
| 2024-12-31 | $1.11M DEF 14A · filed 2026-04-29 |
| 2023-12-31 | $936.74K DEF 14A · filed 2026-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |